A Phase II Study Of Dasatinib (Sprycel®) (IND #73969, NSC #732517) as Primary Therapy Followed by Transplantation for Adults ≥ 18 Years with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG
This phase II clinical trial studies how well dasatinib followed by stem cell transplant
works in treating older patients with newly diagnosed acute lymphoblastic leukemia.
Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth. Giving chemotherapy before a stem cell transplant stops the growth of cancer
cells by stopping them from dividing or killing them. Monoclonal antibodies, such as
alemtuzumab, may interfere with the ability of cancer cells to grow and spread. Giving more
than one drug (combination chemotherapy) and giving dasatinib together with chemotherapy may
kill more cancer cells.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.